36 results about "Endometrial cell" patented technology

The invention provides a stem cell composition for treating endometrial repair. Specifically, the invention also provides an oligopeptide ZGC-5 which can significantly inhibit ectopic endometrial cell proliferation and has therapeutic activity, and the oligopeptide has the effects of inhibiting ectopic endometrial cell proliferation and promoting apoptosis. After the oligopeptide and the stem cells are prepared into the medicine box, the medicine box has a good effect of treating endometriosis.

The invention discloses a biological composite material as well as a preparation method and application thereof. The biological composite material comprises a decellularized biological amnion, mesenchymal stem cells and polypeptide hydrogel. In the polypeptide hydrogel, the sequence of the polypeptide is IGSRVGDRGDS. The biological composite material can effectively promote cell growth at a thin endometrial injury position, endometrial cell proliferation activity is higher, new vessel production related gene regulation activity is enhanced, fibrosis caused by the endometrial injury is well inhibited, re-adhesion after an intrauterine adhesion separation operation is prevented, and a good application prospect is achieved. The fertility is obviously improved, and the pregnancy rate is increased.

The invention discloses a uterus in-situ endometrium and ectopic endometrium organ induced canceration model as well as an establishment method and application thereof. The method comprises the following steps: extracting endometriosis endometrial cells and endometriosis in-situ endometrial cells, and constructing paired endometriosis endometrial organs and endometriosis in-situ endometrial organs; the endometriosis ectopic endometrial organs and the endometriosis in-situ endometrial organs are subjected to passage; the high-concentration estrogen is used for stimulating endometriosis ectopic endometrial organs and endometriosis in-situ endometrial organs; according to the method, endometriosis organs have certain cell nucleus heterogeneity, a monolayer epithelium structure is developed into a proliferative multi-layer epithelium structure, and a cell model which is convenient to construct and observe and can be cultured for a long time is provided for the pathological process of endometriosis into endometrial adenocarcinoma. The method has important scientific significance on the mechanism research of the subsequent endometriosis malignant transformation into the endometrial adenocarcinoma and the research on key molecules at the early stage of the ovarian endometrial adenocarcinoma.

The invention discloses an effectiveness exploration method for inhibiting AM by exciting LIPUS through a flexible ultrasonic patch, and belongs to the field of medical equipment and biomedical engineering. The patch comprises a flexible substrate, an island bridge type metal electrode, an adjustable array type piezoelectric ceramic unit and a flexible packaging layer, can be precisely attached to a focus area, outputs low-intensity pulse ultrasound with the frequency of 1-3 MHz and the sound intensity of 30-120 mW / cm < 2 >, and can inhibit expression of proinflammatory factors, up-regulate E-cadherin, induce apoptosis of ectopic endometrial cells and inhibit activity of pain ion channels, so that the pain of a patient is relieved, and the pain of the patient is relieved. In-vivo and in-vitro experiments show that the patch does not have significant uterus and ovarian toxicity, can reduce the fibrosis area by 40% or more, can increase the apoptosis rate to 45%, supports a continuous or pulse type adjustable treatment mode, integrates a flexible electronic technology and ultrasonic medicine, and has a wide application prospect. A noninvasive, accurate and wearable innovative treatment scheme is provided for adenomyosis, and the clinical transformation value is remarkable.

The invention relates to the technical field of medical gel, and particularly discloses a sustained-release gel preparation for endometrial repair and a preparation method of the sustained-release gel preparation. Keratinocyte factor sustained-release microspheres containing keratinocyte factor-glucan particles and lactic acid-glycolic acid copolymer shells are constructed around keratinocyte factors, and the keratinocyte factor sustained-release microspheres are loaded by hyaluronic acid hydrogel containing polylysine, collagen and silk fibroin to form the sustained-release gel preparation for endometrial repair. The sustained-release gel preparation has the effect of promoting proliferation of human endometrial cells, can repair endometrial injury, promote injury healing and prevent uterine cavity adhesion, and has important significance in treating endometrial injury and improving physical and psychological health of women.

Disclosed are methods for producing controlled endometrial organoids using micropatterning techniques, and methods for using endometrial cells or organoids for diagnostic and predictive purposes, and for optimizing IVF and other infertility-related treatments, including embryo transfer and intrauterine insemination (IUI). These organoids grow in a spatially controlled manner and exhibit less heterogeneity than organoids grown directly in a three-dimensional culture. The specification also describes methods for predicting the success of embryo transfer or other IVF-related treatments, optimizing embryo transfer, improving embryo implantation in the endometrium, and performing embryo transfer in subjects. These methods include culturing endometrial organoids or endometrial epithelial cells, and contacting the endometrial organoids or cells with one or more blast-like cells. In some embodiments, the endometrial organoids or cells include endometrial cells obtained from subjects undergoing or considering IVF-related treatment.

A menstrual blood-derived endometrial cell collection device is provided. [Solution] The device comprises a central hand-held hollow tube 1 and a curette function part 2. Inside are an inner limiting hollow tube and an annular stopper ring with an elastic stopper plate. A rotating knob 6 is attached to the end of the central hand-held hollow tube by a screw connection, and the inclined annular pressure ring of the rotating knob acts on the outside of the elastic stopper plate. The hollow shaft of the curette function part passes through the rotating knob and extends into the inner limiting hollow tube and is positioned by the elastic stopper plate. A friction groove is formed on the outer edge of the rotating knob. This device allows for quick replacement of the curette function part, flexible adjustment of the protrusion length, and excellent portability.

The invention relates to a medicine for recurrent abortion endometrial cell senescence and a preparation process thereof, and belongs to the technical field of traditional Chinese medicine preparations. The medicine is prepared from the following traditional Chinese medicine components: 10 to 30 parts of semen cuscutae, 5 to 15 parts of herba taxilli, 5 to 15 parts of radix dipsaci, 5 to 15 parts of radix angelicae sinensis, 5 to 15 parts of radix scutellariae, 5 to 15 parts of radix paeoniae alba, 5 to 15 parts of rhizoma chuanxiong, 1 to 9 parts of rhizoma atractylodis macrocephalae and 6 to 16 parts of colla corii asini. The medicine has a remarkable curative effect on endometrial cell senescence in an implantation window phase of recurrent abortion. The traditional Chinese medicine preparation is used for treating endometrial interstitial cell senescence in an implantation window phase of unexplained recurrent abortion. The dosage form of the medicine can be any one of clinically acceptable dosage forms such as granules, capsules and tablets, pharmacodynamic experiments prove that the same technical effect can be achieved, and the medicine is suitable for further popularization and application.

The invention discloses a system for endometriosis diagnosis and a computer storage medium. Aiming at major adjustment of endometriosis diagnosis standards, biomarkers and ploidy information of circulating endometrial cells in easily available samples such as peripheral blood of a patient are detected, and comprehensive risk assessment is performed by utilizing an optimization algorithm model, so that the diagnosis accuracy of endometriosis is improved. The invention provides an objective and quantifiable noninvasive diagnostic tool adapted to the adjusted standard, and the method solves the problem of missed diagnosis caused by false negative in the existing surgical diagnostic method, and has important clinical application value, social benefit and market prospect for improving the overall diagnostic level of endometriosis.

The invention relates to an application of a NeuMME subgroup in preparation of a diagnostic kit for evaluating NETosis occurrence degree or endometriosis severity. The invention also provides an application of the NETosis inhibitor or the DNase I in preparation of a medicine for treating endometriosis. It is proved that NETs in the abdominal cavity promote colonization, migration and proliferation capacity of endometrial cells through the capture effect, so that occurrence and development of endometriosis focuses are promoted, the NeuMME subgroup is a main source of the NETs, and therefore detection of the NeuMME subgroup and evaluation of the occurrence degree of NETosis have important significance. In addition, based on clinical sample analysis, it is found that NeuMME subgroups of peritoneal fluid are closely related to clinical rASRM scores of endometriosis; the analysis of a mouse endometriosis model also finds that the NeuMME subgroup is closely related to the occurrence and development of an endometriosis focus. Therefore, the NeuMME-based subgroup detection for evaluating the severity of endometriosis and the focus progress has remarkable advantages and application prospects. The development of endometriosis can be remarkably inhibited by inhibiting NETosis or clearing NETs in a mouse model through a drug.

An in-vitro method for stimulating the gene expression of at least one of XOXA10, LIF, ITGB3, XOXA11 and ITGAV genes in endometrial cells comprising applying on such endometrial cells electric current waves having a sinusoidal waveform with a fundamental frequency higher than 2 MHz, preferably of about 4 MHz, for a predefined amount of time.

The invention belongs to the field of biological materials, and particularly relates to a gel for repairing endometrial injury as well as a preparation method and application of the gel. The invention provides a gel for repairing endometrial injury. The gel is prepared from recombinant I-type humanized collagen, antibacterial peptide and mesenchymal stem cells. The gel provided by the invention can promote proliferation of endometrial cells, repair an endometrial microenvironment, promote regeneration of endometrium and effectively repair damaged endometrium, and has a development prospect in clinical application.

The present invention comprises methods and devices comprising a scraping element used to contact circumferentially and longitudinally the surface walls of the uterine cavity to provide for broad contact of the intended surface with the device, resulting in attainment of a sufficient volume and comprehensive tissue sample for analysis as an endometrial biopsy or screening uterine cancer. The device may provide for a reservoir for the obtained sample to be contained when removing from the uterine cavity, cervical canal, and vagina. The device may be comprised of a detachable means or be of a material that allows the user to cut the sampling head of the device for placement in collection means to maximize the amount of tissue or cells being sent to the laboratory for analysis.

The application discloses a hydrogel for endometrial repair, which is prepared from platelet-rich plasma, benzene boronic acid modified hyaluronic acid methacrylate (HAMA-PBA), phenyl-2,4,6-trimethyl benzoyl phosphonic acid lithium (LAP), calcium chloride (CaCl2) and polyvinyl alcohol (PVA). The application further provides a preparation method of the hydrogel, which comprises the following steps: mixing HAMA-PBA aqueous solution, LAP aqueous solution and CaCl2 aqueous solution to obtain a precursor solution A, dissolving PVA in PRP to obtain a PVA-PRP mixed solution as a precursor solution B, mixing the precursor solution A and the precursor solution B at a volume ratio of 1:1 to obtain PRP@HAMA-PBA-PVA hydrogel, and irradiating the PRP@HAMA-PBA-PVA hydrogel under ultraviolet light to obtain the hydrogel for endometrial repair. The hydrogel can significantly promote endometrial cell proliferation, has strong pro-angiogenic characteristics, inhibits endometrial fibrosis, and thus comprehensively repairs the endometrial microenvironment, promotes endometrial regeneration and improves embryo implantation rate and live birth rate.

The application discloses high-adhesion modified mesenchymal stem cells and application thereof in preparation of a medicine for treating intrauterine adhesion. The modified mesenchymal stem cells are genetically engineered to overexpress integrin alpha 2 subunit and / or integrin alpha 5 subunit, thereby enhancing the adhesion capacity to the extracellular matrix (collagen and fibronectin) of the endometrium. In vitro experiments show that the initial adhesion rate, liquid flushing resistance and anoikis resistance of the modified MSCs are significantly better than those of common MSCs. When used in combination with the "dynamic culture and drug delivery device for intrauterine adhesion treatment" applied by the inventor on the same day, the retention rate of the modified MSCs in the simulated intrauterine dynamic culture environment is significantly improved. Animal experiments show that the modified MSCs in combination with the device can significantly promote endometrial regeneration, inhibit fibrosis and improve the pregnancy rate. The application solves the core bottleneck of low cell retention rate and short survival time in the MSC transplantation treatment of intrauterine adhesion by enhancing the adhesion capacity of the MSCs, and forms a complete treatment scheme in cooperation with the device, thereby having a good clinical application prospect.

The invention discloses establishment and application of a human ovarian ectopic inner membrane cell strain (HOEEC) based on SV40T gene transfection, and relates to the technical field of biology, and the establishment comprises the following steps: S1, collecting a specimen; s2, isolated culture of human ovarian ectopic inner membrane primary cells; s3, amplification and extraction of plasmids; s4, performing lentivirus transfection to establish a human ovarian ectopic inner membrane cell strain; the method comprises the following steps: firstly, extracting and separating to obtain primary cells of the human ectopic ovarian endometrium, then establishing the human ectopic ovarian endometrium cell strain by transfecting SV40T, comparing the differences between the HOEEC and the primary cells in the aspects of cellular morphology, passage condition, multiplication capacity, invasion capacity, hormone receptor expression and estrogen reaction, and detecting the number and morphology of HOEEC chromosomes and the existence of in-vivo tumorigenicity. A new human ovarian ectopic endometrial cell strain is established by transfecting the SV40T gene for the first time, and an in-vitro model is provided for studying the pathogenesis of ovarian endometriosis.

The utility model discloses a menstrual blood endometrial cell collecting device which comprises a collecting barrel, a limiting groove is formed in the collecting barrel, a push plate is connected in the limiting groove in a sliding mode, a connecting rod is fixedly connected to the top of the push plate, a cotton sleeve is arranged on the surface of the connecting rod in a sleeved mode, and the cotton sleeve is connected with the limiting groove in a sliding mode. The bottom of the cotton sleeve is attached to the top of the push plate through an adhesive, the surface of the cotton sleeve makes contact with the inner wall of the collecting barrel, the bottom of the push plate is fixedly connected with a push-pull rod, the bottom of the push-pull rod penetrates to the bottom of the collecting barrel, and a protection mechanism is arranged on the surface of the collecting barrel. The vagina endometrial cell collecting device can effectively collect menstrual blood endometrial cells on the inner wall of the vagina, avoids the phenomenon that an operator rubs with overexertion when using a cotton swab for collection, enhances the practicability of the collecting device, and prevents the problem that a collected person feels uncomfortable when the operator rubs the inner wall of the vagina with the cotton swab.

The invention relates to a medicine for endometrial cell senescence and a preparation process thereof, and belongs to the technical field of traditional Chinese medicine preparations. The medicine comprises the following traditional Chinese medicine components: 10-30 parts of semen cuscutae, 5-15 parts of herba taxilli, 5-15 parts of radix dipsaci, 5-15 parts of radix angelicae sinensis, 5-15 parts of radix scutellariae, 5-15 parts of radix paeoniae alba, 5-15 parts of rhizoma chuanxiong and 1-9 parts of rhizoma atractylodis macrocephalae, and has a remarkable curative effect on endometrial cell senescence in the implantation window phase of recurrent abortion. Pharmacodynamic experiments prove that the suppository prepared from the traditional Chinese medicine disclosed by the invention can be used for remarkably improving endometrial cell senescence, especially endometrial cell senescence in an implantation window stage (WOI) of recurrent abortion (URSA). The dosage form of the medicine can be suppositories, granules, capsules and the like, pharmacodynamic experiments prove that the same technical effect can be achieved, and the preparation is simple in preparation technology and suitable for further popularization and application.

The invention relates to the field of high-performance composite materials, in particular to an embryo cryopreservation cell carrier scaffold material and a preparation method of the embryo cryopreservation cell carrier scaffold material. The total amount is 100%: 50.0 to 65.0 weight percent of gelatin, 20.0 to 35.0 weight percent of silk fibroin, 5.0 to 12.0 weight percent of sodium hyaluronate, 3.0 to 8.0 weight percent of chitosan, 0.1 to 2.0 weight percent of RGD polypeptide and 0.5 to 3.0 weight percent of anti-ice crystal forming polypeptide AFP III, the gelatin, hyaluronic acid and silk fibroin ternary composite system simulates biochemical components and physical characteristics of an endometrial extracellular matrix, provides similar in-vivo microenvironment support for embryos, and is beneficial to maintaining embryo activity.

The invention discloses a sampler for collecting endometrial cells or tissue samples and a use method of the sampler, and belongs to the technical field of medical instruments, and the sampler comprises a flexible catheter and a deformable inner core guide wire; the inner core guide wire is made of hyperelastic shape memory alloy, the inner core guide wire is composed of a near-end rod body and a far-end self-adaptive brush head, and when the far end of the inner core guide wire is pushed out of the flexible catheter, the self-adaptive brush head is automatically unfolded to form an inverted triangular frame; a plurality of flexible bristles with Shore A hardness of 10A-30A are distributed on the self-adaptive brush head in a three-dimensional gradient manner; the invention further provides an application method. According to the invention, through the combination of the'automatically unfolded inverted triangular brush head 'and the'three-dimensional gradient distributed soft bristles', the shape self-adaption and full-coverage sampling of the uterine fundus and the uterine horn of the uterine cavity are realized, and the omission ratio is obviously reduced; the ultra-thin flexible catheter is combined with the extremely-soft bristles, so that the full-path noninvasive and safe operation from the hymen to the endometrium is ensured, and the applicable crowd is expanded.

A method for treating a subject having. or at risk of having. damaged endometrial tissue generally includes administering to the subject an amount of a PEP preparation effective to treat the subject's endometrial tissue. The PEP preparation may be administered therapeutically or prophylactically. In another aspect. a method of promoting proliferation of endometrial cells generally includes contacting the endometrial cells with an amount of a PEP preparation effective to promote proliferation of the endometrial cells. In another aspect. a method of promoting wound closure by endometrial cells generally includes administering to endometrial cells into which a wound has been introduced an amount of a PEP preparation effective to promote closure of the wound.

The invention provides a pharmaceutical preparation for repairing endometrial injury, and belongs to the technical field of biomedicine. The pharmaceutical preparation takes improved polypeptide as an active ingredient, and the amino acid sequence of the improved polypeptide is shown as SEQ ID NO.5. Experimental results show that the polypeptide can significantly promote proliferation and migration of human endometrial stromal cells, still maintains low cytotoxicity under high concentration, and shows excellent safety. Furthermore, in a rat endometrial mechanical injury model, the preparation can obviously increase the endometrial thickness, improve the Ki-67 positive cell rate, enhance the proliferation activity of endometrial cells and promote the repair of damaged tissues. Compared with the original polypeptide, the preparation disclosed by the invention shows unexpected technical effects in the aspects of repairing activity and safety, and has a good application prospect.

The present invention belongs to the field of biomaterials, and specifically relates to a gel for repairing endometrial damage, and a preparation method and application thereof. The present invention provides a gel for repairing endometrial damage, and the gel comprises recombinant humanized type I collagen, antimicrobial peptides and mesenchymal stem cells. The gel of the present invention promotes the proliferation of endometrial cells, repairs the endometrial microenvironment, promotes endometrial regeneration, effectively repairs damaged endometrium, and has development prospects for clinical application.

The utility model relates to a collector applied to endometrial cells and tissues. The collector comprises a catheter, an elastic skeleton, a movable strip, a seat body and a flow channel structure, a medical worker guides the insertion end of the catheter into the uterine cavity of a patient, then the elastic framework at the connecting end is gradually pushed out of the insertion end by pushing the operation end of the movable strip, the elastic framework is outwards unfolded under the action of self elasticity, and the medical worker can drive the movable strip and the elastic framework to synchronously rotate by rotating the operation end; and the cells and tissues of the endometrium can be scraped by the outline of the elastic skeleton, so that the cells and tissues fall into the uterine cavity. After the operation of scraping the cells and the tissues of the endometrium is completed, a medical worker can connect an upper negative pressure device at the collection interface on the seat body, and the scraped cells and the tissues in the uterine cavity are fully extracted through the flow channel structure, so that the collection of the cells and the tissues of the endometrium is completed. Compared with the prior art, the collector has the advantage of high collection efficiency.

Methods and devices for non-thermal treatment of endometriosis. The non-thermal treatment of endometrial lesions results in electroporation of the endometrial cells, and ultimately necrosis of the lesion. Lesions are identified and electric field parameters determined to substantially remove all of the endometrial cells in the target lesion. Application of the electric field to the lesion creates a treatment zone where the cells necrose, leaving the cellular matrix mostly undisturbed. Devices include a generator capable of applying an electric field to an endometrial lesion through one or more electrodes.

The invention discloses a molecular marker for promoting proliferation of sheep endometrial cells and application of the molecular marker, and relates to the field of gene agriculture, the molecular marker is oar-miR-493-3p, and the sequence of the oar-miR-493-3p is 5 '-UGAAGGUCUACUGUGUGCCAGG-3' SEQ ID No: 01; the invention finds that the molecular marker oar-miR-493-3p can increase the expression quantity of receptivity related genes AREG and LTF, and promote the proliferation of sheep endometrial cells; the method is widely applied to the field of sheep reproduction diagnostic kits, and can be used for early pregnancy diagnostic kits or embryo implantation diagnostic kits and the like.

This invention relates to an endometrial cell collector, comprising an outer sheath, a sampling handle, and sampling brushes. The sampling handle is inserted inside the outer sheath, with one end extending out of the sheath. Multiple sampling brushes are arranged side-by-side, each rotatably mounted within the sampling handle and radially arranged along it. The length of each sampling brush is greater than the length of the sampling handle, with both ends extending out of the handle. Each sampling brush has a brush head at one end. When the sampling handle approaches the outer sheath axially, the brush head extends out of the sheath, and the extended brush heads are arranged in a fan shape to expand the contact area with the uterine cavity, reaching both uterine horns. The multiple sampling brushes arranged side-by-side within the outer sheath can extend and retract under the push and pull of the sampling handle. The fan-shaped arrangement of the extended brush heads ensures coverage throughout the entire uterine cavity, preventing missed sampling.

The application discloses an endometrium-targeted mitochondrial function compensation system and application thereof. The endometrium-targeted mitochondrial function compensation system comprises a function unit, a delivery unit and a control unit. The function unit comprises a vesicle preparation formed by wrapping donor mitochondria with red blood cell membranes. The donor mitochondria are isolated mitochondria with complete inner and outer mitochondrial membranes and ridge structures or engineered mitochondria carrying exogenous mitochondrial DNA. The application first constructs a comprehensive system integrating biological active ingredients, targeted delivery and intelligent control, can directly and efficiently repair the mitochondrial function of endometrial cells, promote endometrial proliferation, and provides an innovative solution for treating related reproductive diseases. The system has complete design, clear effect and good clinical transformation prospect.

The present invention discloses a method, system, device and storage medium for detecting endometrial cancer cells, including: preparing endometrial cell pathological sections; preliminarily screening images containing positive cells by using CNN; performing intelligent detection of cancer cells by using an improved Faster R-CNN object detection model; counting various indicators, generating patches from WSI and sending them into the network for prediction, and then merging the recognition results. In the part of target acquisition, the data set is normalized and expanded by using the method of adaptive random cropping; on the model, an improved CNN model and a two-stage Faster RCNN model are used as the basic models, and the doctor's diagnosis experience is introduced, and diagnostic indicators are extracted and jointly used to train a more accurate model. The accuracy of the endometrial cancer cell detection method of the present invention is higher than that of the classification method, and at the same time, the confidence level and the position information of the WSI can be given. In addition, the present invention also provides a more effective method for preparing an endometrial cell pathological section image data set. The present invention is applied to the field of medical image object detection.

Use of an exosome derived from decidual natural killer (dNK) cells or a dNK cell subset in the preparation of a drug and an auxiliary therapeutic agent for infertility-related diseases is provided. Experiments have confirmed that the exosome treats the endometrial growth disorder-related diseases by promoting increase of endometrial thickness, increasing endometrial cell viability, reducing endometrial cell damage, promoting VEGF expression, and maintaining stemness and stimulating proliferation of endometrial stromal cells, such that a conception rate for endometrial injury model mice increases from 20% to 50%-70%; and the exosome treats the maternal-fetal immune tolerance disorder-related diseases by exerting immune tolerance, reducing a spontaneous abortion rate, and increasing a helper T cell level. In addition, the exosome effectively increases the development rate of eggs fertilized in vivo or in vitro in a multiplying way, and improves an implantation rate and a birth rate for in vitro fertilization and embryo transfer.